Dr. Victor Kiri has been appointed director of pharmacoepidemiology within Parexel International's Clinical Research Services business. Dr. Kiri will be responsible for advising clients in the design and conduct of comparative observational studies, offering epidemiological analysis for compounds in development, and guiding strategic decisions regarding future areas of research and product development.
"Regulatory pressures are increasing client demand for pharmacoepidemiological assessments and related studies as part of late phase clinical development," said Mark A. Goldberg, M.D., president of Clinical Research Services and Perceptive Informatics at Parexel. "One of Parexel 's strengths is our late phase development service offering that we call Peri-Approval Clinical Excellence or PACE. Dr. Kiri's in-depth experience in late phase study design and safety-related issues further expands our capabilities to provide clients with integrated pharmacoepidemiology and pharmacovigilance solutions."
Prior to joining the company, Dr. Kiri managed epidemiology research at GlaxoSmithKline. He previously served as a consultant on health outcomes to the U.K. Department of Health for more than 15 years. Dr. Kiri has been appointed as Adjunct Professor of Biostatistical Epidemiology at the University of Limerick in Ireland. He also served as a lecturer at the London School of Hygiene and Tropical Medicine and at the Department of Epidemiology at the University of Surrey, in the U.K. Dr. Kiri has been elected as a Chartered Statistician by the U.K. Royal Statistical Society.